Bochum (ots) – BELKIN Vision offers a new type of laser therapy for some of the approximately 900,000 people with glaucoma.[1] What is special compared to previous laser interventions is that direct contact with the eyes is no longer necessary, which makes the treatment particularly gentle: a step forward for doctors and patients.
Patient-oriented: Fewer eye drops following Eagle treatment with 120 laser pulses
The laser, BELKIN Vision EagleTM, fires 120 laser pulses into the eye to lower the intraocular pressure associated with glaucoma. The laser procedure is patient and user-friendly, because with the conventional laser procedure (SLT) for the treatment of glaucoma, the chamber angle had to be made visible through direct contact with the eye (gonioscopy). The BELKIN Eagle can be used by all ophthalmologists following completing the training. In this way, more patients can be treated with laser treatment as initial therapy in accordance with the European directive. So far, many patients have used eye drops for everyday therapy. In the pivotal studies, the use of the BELKIN Eagle showed that around 70% of the patients who received DSLT as initial treatment no longer needed eye drops one year following treatment. Reducing the use of eye drops to treat glaucoma is a critical success factor in treating the disease, as these eye drops can have side effects and are often overlooked.
User-oriented: Gentle and automatic
“We have the opportunity to treat more of those affected with the gentle and automated procedure. The laser does not require direct contact with the eyes and can reduce or even completely replace the need for eye drops. This gives the patient an uncomplicated, rapid treatment for prolapse of the intraocular pressure and thus more quality of life once more,” said Prof. Dr. Burkhard Dick, director of the eye clinic at the University Hospital Bochum Knappschaftsklinikum of the Ruhr University.
BELKIN Vision: User- and patient-friendly therapy
“This is a very special moment for BELKIN Vision. We are convinced that the Eagle with its DSLT technology will make a remarkable difference for glaucoma patients in Germany and eventually around the world,” said Daria Lemann-Blumenthal, Managing Director of BELKIN Vision. “We are thrilled to finally be able to offer care for glaucoma patients that can be used as first-line therapy.”
The Eagle received CE Mark approval in May 2022 as the first automated, non-contact glaucoma laser treatment in Europe. In addition to Germany, the device will be launched in the European market, including Great Britain and Italy, in the coming months.
About glaucoma disease
Glaucoma is a chronic eye disease that affects nearly 150 million people worldwide.[2] There are currently an estimated 900,000 patients in Germany.
Left untreated, glaucoma can damage the optic nerve and is the leading cause of irreversible blindness worldwide.[3]
About BELKIN
BELKIN Vision is an Israeli medical technology company founded in 2013. BELKIN Vision makes Direct Selective Laser Trabeculoplasty (DSLT) available as first-line glaucoma therapy to a large number of ophthalmologists, so that optimal glaucoma therapy can be carried out close to the time of diagnosis. Visit the BELKIN Vision website to learn more.
Related Links:
www.belkin-vision.com
BELKIN Vision LinkedIn
BELKIN Vision YouTube
For press photos, please visit Dropbox
credentials
[1]
[2] 2022 Glaucoma Disease Model, March, 2022
[3]
Questions & contact:
GCI Health management consultancy for communication GmbH
Shanghaiallee 7
20457 Hamburg
Dr. Stephanie Schruhl
T: +49 151 12515718
Stephanie.schruhl@gcihealth.de
